Genetic determined low response to thienopyridines is associated with higher systemic inflammation in smokers

: To investigate whether the interactions of and with smoking are associated with the levels of P2Y12 receptor inhibition and CRP, in on-thienopyridine post-stenting patients. : At 1-month follow-up, the interactions of smoking and polymorphisms on the vasodilator-stimulated phosphoprotein - platelet reactivity index (VASP PRI), and CRP were explored in three metabolizing groups (1128 patients) as follow: poor metabolizers ( carriers/ noncarriers); intermediate metabolizers ( carriers/ carriers or noncarriers/ noncarriers); and ultrarapidmetabolizers ( allele noncarriers/ carriers). The interactions of metabolizing status and smoking was significant for CRP (p = 0.001) but not for VASP PRI (p = 0.734). : Interaction between polymorphisms and smoking modifies on-treatment CRP level of post-stenting, on-thienopyridine patients. This effect seems to be independent to the level of P2Y12 receptor inhibition. Original submitted 1 August 2014; Revision submitted 4 February 2015